Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; hyprolose; sodium starch glycollate type a; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hyprolose; magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; purified talc; microcrystalline cellulose; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hyprolose; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; sodium starch glycollate type a; purified talc; hyprolose; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: hyprolose; croscarmellose sodium; iron oxide red; magnesium stearate; hypromellose; iron oxide yellow; macrogol 6000; titanium dioxide; lactose monohydrate; microcrystalline cellulose - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hypromellose; sorbitan stearate; magnesium stearate; titanium dioxide; purified talc; triacetin; iron oxide yellow - tadalafil sandoz is indicated for the treatment of erectile dysfunction (ed) in adult males

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hypromellose; sorbitan stearate; magnesium stearate; titanium dioxide; purified talc; triacetin; iron oxide yellow - tadalafil sandoz is indicated for the treatment of erectile dysfunction (ed) in adult males